| Filed On | Filing |
|---|---|
| 03 Nov 2026 |
8-K: Completion of Acquisition or Disposition of Assets; Results of Operations and Financial Condition +1 more
Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027 |
| 19 Oct 2026 |
8-K: Other Events
On October 19, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) and Baylor Research Institute (“BRI”) entered into a settlement agreement with Navinta LLC (“Navinta”) resolving patent litigation related to patents covering the Compan... |
| 14 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
On October 8, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) entered into an asset purchase agreement (the “PRV Asset Purchase Agreement”), pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority Review Vouch... |
| 07 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
On October 6, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) entered into an asset purchase agreement (the “PRV Asset Purchase Agreement”), pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority Review Vouch... |
| 17 Sep 2026 |
8-K: Other Events
On September 17, 2026, Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) announced that the U.S. Food and Drug Administration (the “FDA”) granted standard full approval of FAYUVI™ (rebisufligene etisparvovec-hopf), also know... |
| 02 Sep 2026 |
8-K: Other Events
On September 2, 2026, Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) announced results from the Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome. The study did not achieve the primary endpoint of change... |
| 19 Aug 2026 |
8-K: Other Events
On August 19, 2026, Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) announced the U.S. Food and Drug Administration (the “FDA”) granted accelerated approval for GENGLYCOS™ (pariglasgene brecaparvovec-opnr), also known as D... |
| 11 Aug 2026 |
8-K: Other Events
On August 7, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) and Baylor Research Institute (“BRI”) entered into a settlement agreement with Esjay Pharma Private Limited and Esjay Pharma LLC (collectively, “Esjay”) resolving patent l... |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
Crysvita® revenue of $156 million and Dojolvi® revenue of $27 million |
| 18 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Exhibit A, which is incorporated by reference, defines the terms used in the Plan and sets forth certain operational rules related to those terms. |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
Crysvita® revenue of $93 million and Dojolvi® revenue of $18 million |
| 02 Apr 2026 |
8-K: Other Events
On April 2, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (the “FDA”) has accepted for review the Company’s resubmitted Biologics License Application see... |
| 30 Mar 2026 |
8-K: Other Events
On March 30, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (the “FDA”) has cleared the Investigational New Drug (“IND”) application for UX016, an investi... |
| 12 Mar 2026 |
8-K: Other Events
On March 12, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) issued a press release announcing positive results from its Phase 3 Enh3ance study of DTX301, an investigational AAV8 gene therapy for the treatment of ornithine transcarb... |
| 23 Feb 2026 |
8-K: Other Events
On February 23, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (the “FDA”) has accepted for review the Biologics License Application (the “BLA”) seeking a... |
| 12 Feb 2026 |
8-K: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities
Crysvita® revenue of $481 million and Dojolvi® revenue of $96 million |
| 03 Feb 2026 |
8-K: Other Events
On February 3, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) issued a press release announcing new long‑term data from clinical studies evaluating UX111 (rebisufligene etisparvovec), an investigational AAV9 gene therapy for Sanfil... |
| 30 Jan 2026 |
8-K: Other Events
On January 30, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) issued a press release announcing that that it has resubmitted its Biologics License Application (“BLA”) seeking accelerated approval for UX111 (rebisufligene etisparvov... |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition
Preliminary 2025 total revenue of $672 million to $674 million, exceeding top end of guidance |
| 30 Dec 2025 |
8-K: Other Events
On December 30, 2025, Ultragenyx Pharmaceutical Inc. (the “Company”) issued a press release announcing that that it has completed the rolling submission of its Biologics License Application (“BLA”) to the U.S. Food and Drug Administratio... |
Loading...